在停牌长达一年半之后，TATA健康（01255.HK）终于在12月1日复牌，复牌当日涨幅达566.67%，收盘价报2.00港元/股。 复牌后爆涨源于市场对其长期停牌后恢复交易的积极反应，但这份积极却并没有维持多久，在接下来的几天里TATA健康股价一路下跌，12月12日以1.6港元/ 股收盘，跌幅达37.50%。 据了解，2024年上半年，TATA健康因缺乏营运资金、未能凑齐审计所需附属公司资料，无法按时发布2023年年度业绩而停牌。在这背后是其上市十余年来 却盈利寥寥，多元化业务宽泛却均为拖累的困境。 提起TATA，人们通常会联想到长年驻扎在各大商场的TATA女鞋或是在装潢行业驰骋多年的TATA木门。实际上，TATA健康前身是港大零售国际控股有限公 司，2013年登陆港交所，公司前期的核心业务也为鞋类产品销售，代理了Clarks、Josef Seibel等多个品牌的鞋类产品，但与TATA女鞋这个品牌毫无关联；后 期公司又转型聚焦大健康领域，并开通金融服务业务欲形成跨界业务补充，成为一家综合型公司。 相比于TATA健康形形色色的多元化业务，其上市以来的业绩则更为引人"瞩目"，从完整的财年来看，2013年上市之后 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: TATA健康國際控股有限公司 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01255 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.01 | HKD | | 5,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.01 | HKD | | ...

Group 1 - TATA Health (1255.HK) resumed trading after more than 1.5 years and saw a significant increase, with midday gains reaching 723.33%, trading at HKD 2.47 [1] - The company is primarily engaged in shoe retail in Hong Kong and has met all resumption guidelines, including publishing outstanding financial results and demonstrating business viability [1] - The trading volume exceeded HKD 17 million, indicating strong market interest following the resumption [1]

Core Viewpoint - TATA Health (01255) has resumed trading after more than 1.5 years, experiencing a significant price surge of over 500%, reaching HKD 1.86 with a trading volume of HKD 6.33 million [1] Summary by Relevant Sections - **Resumption of Trading** - TATA Health has successfully met all resumption guidelines, allowing it to resume trading after a prolonged suspension [1] - **Financial Performance and Compliance** - The company has published all outstanding financial results and addressed any audit revisions [1] - TATA Health confirmed that its business operations are sustainable and that it possesses sufficient operational capacity and valuable assets to support its business activities [1] - **Internal Controls** - An independent internal control review has been conducted, demonstrating that the company has established adequate internal controls and procedures to fulfill its responsibilities under listing rules [1]

消息面上，TATA健康发布公告称，公司已达成所有复牌指引，主要包括︰刊发所有未刊发财务业绩及 处理任何审核修订；集团业务持续可行，且有足够的业务运作及相当价值的资产以支持业务营运；及进 行独立内部控制审查，并证明公司已建立充分的内部控制及程序，以履行其于上市规则项下的责任。 TATA健康(01255)时隔逾1年半复牌，早盘飙升超500%，截至发稿，涨520%，报1.86港元，成交额 633.12万港元。 ...

Core Viewpoint - TATA Health (01255) has resumed trading after more than 1.5 years, experiencing a significant price surge of over 500% in early trading, reaching HKD 1.86 with a trading volume of HKD 6.33 million [1] Summary by Relevant Sections - **Resumption of Trading** - TATA Health has successfully met all resumption guidelines, allowing it to resume trading after a prolonged suspension [1] - **Financial Performance and Compliance** - The company has published all outstanding financial results and addressed any audit revisions, ensuring compliance with regulatory requirements [1] - **Business Viability** - TATA Health confirmed that its business operations are sustainable, with sufficient operational capacity and valuable assets to support ongoing business activities [1] - **Internal Controls** - An independent internal control review has been conducted, demonstrating that the company has established adequate internal controls and procedures to fulfill its responsibilities under listing rules [1]

Group 1 - TATA Health (01255.HK) announced that its shares will resume trading at 9:00 AM on December 1, 2025 [1]

Core Viewpoint - TATA Health (01255) has met all resumption guidelines and has applied to the Stock Exchange for the resumption of trading of its shares starting from December 1, 2025, at 9:00 AM [1] Summary by Relevant Sections - Company Status - TATA Health has achieved compliance with all necessary resumption guidelines [1] - The company has submitted an application to the Stock Exchange for the resumption of trading [1] - Trading Resumption - Shares of TATA Health are set to resume trading on December 1, 2025, at 9:00 AM [1]

Core Viewpoint - TATA Health has successfully met all resumption guidelines and will resume trading on the Hong Kong Stock Exchange on December 1, 2025 [1] Group 1 - The company has announced to its shareholders and potential investors that it has fulfilled all requirements for resumption [1] - Trading of the company's shares has been suspended since April 0, 2024, at 9:00 AM [1] - The application for resumption of trading has been submitted to the Stock Exchange [1]

應本公司要求，股份已於二零二四年四月二日上午九時正起暫停買賣。由於所有 復牌指引均已達成，本公司已向聯交所申請股份自二零二五年十二月一日上午九 時正起於聯交所恢復買賣。 本公告乃由TATA健康國際控股有限公司（「本公司」，連同其附屬公司，統稱「本集 團」）根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第13.09 條及香港法例第571章證券及期貨條例第XIVA部項下的內幕消息條文（定義見上市 規則）而作出。 達成所有復牌指引 董事會欣然知會其股東及潛在投資者，於本公告日期，本公司已達成所有復牌指 引。 恢復買賣 TATA Health International Holdings Limited TATA 健 康 國 際 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1255） (1)達成所有復牌指引；及 (2)恢復買賣 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 達成所有復牌指引 董事會欣然宣佈，截 ...